Meeting of the Myeloid Minds- Bridging the Gaps in Leukemia & MDS in Beautiful Miami Rami komrokji Sanam Loghavi, MD صنم لغوی 🔬🧬 Marlise R. Luskin MD, MSCE @KateLaiMD_MPH Andrew Brunner Amer Zeidan MBBS,MHS ‏عامر زيدان Eunice Wang MD Hetty Carraway Namrata Chandhok OncLive.com

#ASCO25 #CML “best choice of frontline TKI for CML” educational session, presented by Dr. Timothy Hughes. 1. No TKI is best for every pts, choice should be individualized based on pt profile. 2. Asciminib may be a better choice for younger pt looking for TFR, except for ASXL1,

Döhle Body vs. May-Hegglin Inclusion

Highlight groundbreaking and emerging science by leading a ASH Poster Walk at the world’s largest #hematology event. 📅 Deadline: August 7, 2025 11:59 Pacific Time Submit to lead a Poster Walk at the 67th ASH Annual Meeting and Exposition: ow.ly/Oa7b50W2zpM #ASH25

It was time to donate. Honoring two of the best ⁦Jud Logan 4x Olympian⁩ ⁦Hetty Carraway⁩

Thrombosis risk in MPN patients peaks within 2 years of diagnosis and is later driven by age. This nationwide study highlights the need for early management and age-specific care to optimise outcomes. buff.ly/SdEag9q

#EHA2025 #youngEHA Bleximenib with AZA+VEN for R/R and ND AML 👇🏽 presented by Dr. Andrew Wei #leusm #menin_inhibitors

#EHA2025 #Revumenib in combination with VEN+AZA for ND #AML #BEAT_AML presented by Dr. Zeidner #youngEHA #leusm

#EHA2025 #youngEHA Great presentation by Dr. DiNardo, how to improve on VEN+HMA for intensive ineligible AML pts.. 1. Ven resistance mechanisms. 2. Novel targets 3. Ven triplets under development #leusm #AML #venetoclax_4_AML

"When you get Danny Logan back, the world's better... WE'RE BETTER." Opponents are averaging single-digits when No. 91 is suited up.

check out this new manuscript featuring Wendy Stock as co-author that looks at cytarabine pharmacogenomics in children/AYAs with AML pubmed.ncbi.nlm.nih.gov/40549387/

🚀 If you are a young haematologist, early-career researcher, or health professional with an interest in cellular therapy or transplant? Get involved with our work at @EBMT – a great opportunity to learn, collaborate, and make an impact! #CellTherapy #Transplant #EBMT

Day 2 begins! Robert Hasserjian discusses molecular classification advances in MDS VJHemOnc #iwMDS25 #iwMPN25 #MDS #MolecularDiagnostics

I always consider hematologic malignancy in a suspected vasculitis diagnosis- ideally with Hetty Carraway ACR_Journals acrjournals.onlinelibrary.wiley.com/doi/10.1002/ar…

Venetoclax in MDS: latest insights from Yazan Madanat VJHemOnc #iwMDS25 #iwMPN25 #Venetoclax #MDS

What an amazing International Consortium for MDS (icMDS) #iwmdsmpn25 #iwmds #iwmds25 workshop with brilliant exchange of ideas & many collaborations to purse to help patients with #MDSsm. A big highlight was celebrating the life achievement awards to 2 MDS legends Dr Pierre Fenaux & Dr Ghulam Mufti. VJHemOnc

Our latest video is out and this time it's back to basics! cherians's video "What is flow cytometry?" gets you started! This video is available for free but for more, sign up for ICCS membership: cytometry.org/web/membership… Check out the video here! 👇 youtu.be/n7UULWuPSsg?si…

Delighted to collaborate on this study led by Jie Liu Kelly Bolton MD PhD describing how germline genetic variation influences the trajectory of clonal hematopoiesis to hematologic malignancy nature.com/articles/s4158… Nature Genetics

Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN. Can we predict the risk for second blood cancer in myeloma pts? Grateful for the collaboration with UChicagoCancerCenter myeloma program. nature.com/articles/s4137…

Hematologists are problem-solvers. I’m proud to support the #Fight4Hematology to fund bold research and training that pushes our field forward. Donate Now (donate.hematology.org/s/)